This document provides an overview of immunosuppressive drugs. It begins with an introduction to immunosuppression and the roles of immunosuppressive drugs in treating autoimmune diseases and preventing organ transplant rejection. The document then classifies immunosuppressive drugs and discusses several classes in more detail, including glucocorticoids, calcineurin inhibitors like cyclosporine and tacrolimus, sirolimus, cytostatics like cyclophosphamide, and mycophenolate mofetil. For each drug, the document provides information on mechanisms of action, indications, dosages, and side effects. The document aims to provide clinicians an overview of commonly used immunosuppressive drugs.
Immunosuppressant are drugs or medicines that lower the body's ability to reject a transplanted organ. Another term for these drugs is anti-rejection drugs. There are 2 types of immunosuppressants: Induction drugs: Powerful antirejection medicine used at the time of transplant.
Immunosuppressants are drugs or medicines that lower the body's ability to reject a transplanted organ. Another term for these drugs is anti-rejection drugs. There are 2 types of immunosuppressants:
Induction drugs: Powerful antirejection medicine used at the time of transplant
Maintenance drugs: Antirejection medications used for the long term.
Immunosuppressant are drugs or medicines that lower the body's ability to reject a transplanted organ. Another term for these drugs is anti-rejection drugs. There are 2 types of immunosuppressants: Induction drugs: Powerful antirejection medicine used at the time of transplant.
Immunosuppressants are drugs or medicines that lower the body's ability to reject a transplanted organ. Another term for these drugs is anti-rejection drugs. There are 2 types of immunosuppressants:
Induction drugs: Powerful antirejection medicine used at the time of transplant
Maintenance drugs: Antirejection medications used for the long term.
A power point presentation on Pharmacodynamics (what drug does to the body) suitable for undergraduate medical students beginning to study Pharmacology
A power point presentation on Pharmacodynamics (what drug does to the body) suitable for undergraduate medical students beginning to study Pharmacology
Anticoagulant, classification of anticoagulant
Classification of Heparin and Warfarin ( mechanism of action, clinical use,pharmacokinetics, adverse drug reaction,contraindications)
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
2. OUTLINE
• Introduction
• Role of immunosuppressive drugs
• Classification
• Immunosuppressive drugs
> Glucocorticoid
> Cytostatics
> Antibodies
> Drugs acting on immunophilins
> Other drugs
• Drug monitoring
• Drug summary
3. INTRODUCTION
• Immunosuppression involves an act that reduces the activation or efficacy
of the immune system
• Immunosuppressants are used to control severe manifestations of allergic,
autoimmune and transplant-related diseases
• Immunosuppression is typically done using drugs, but may involve surgery
(splenectomy), plasmapharesis, or radiation
• Clinically they are used to
> Prevent the rejection of transplanted organs and tissues
> Treatment of autoimmune diseases or diseases that are most likely of
autoimmune origin
> Treatment of some other non-autoimmune inflammatory diseases
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
5. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
AUTOIMMUNE DISEASES
KOVARIK J. FROM IMMUNOSUPPRESSION TO IMMUNOMODULATION: CURRENT PRINCIPLES AND FUTURE STRATEGIES. PATHOBIOLOGY 2013;80:275–281.
6. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
7. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
8. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
• Patterns of allograft rejection
> Hyperacute rejection
> Acute rejection
> Chronic rejection and graft vasculopathy
9. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
• Hyperacute rejection is
characterized by thrombotic
occlusion of the graft vasculature
• Begins within minutes to hours after
host blood vessels are anastomosed
to graft vessels
• Mediated by preexisting antibodies
in the host circulation that bind to
donor endothelial antigens
10. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
• Acute rejection is a process of injury to the graft parenchyma and blood
vessels
> Acute cellular injection
> Acute antibody mediated rejection
• Mediated by alloreactive T cells and antibodies
• Before modern immunosuppression, acute rejection would often begin
several days to a few weeks after transplantation
• In current clinical practice, it may occur at much later times, even years
after transplantation
11. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
12. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
ABBAS AK, ET AL. TRANSPLANTATION IMMUNOLOGY. CELLULAR AND MOLECULAR IMMUNOLOGY (9TH ED) 2018.
• A dominant lesion of chronic
rejection in vascularized grafts is
arterial occlusion as a result of the
proliferation of intimal smooth muscle
cells
• The grafts eventually fail mainly
because of the resulting ischemic
damage
13. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
HALLORAN PF. IMMUNOSUPPRESSIVE DRUGS FOR KIDNEY TRANSPLANTATION. N ENGL J MED 2004;351:2715-29.
14. ROLE OF IMMUNOSUPPRESSIVE DRUGS:
ORGAN TRANSPLANTATION
HALLORAN PF. IMMUNOSUPPRESSIVE DRUGS FOR KIDNEY TRANSPLANTATION. N ENGL J MED 2004;351:2715-29.
18. GLUCOCORTICOID
• Corticosteroids are the mainstay of most immunosuppressive regimens in
both the induction and maintenance phases
• In high intravenous pulse doses, they are directly lymphocytotoxic
• In smaller doses, they are immunosuppressive and anti-inflammatory by
limiting cytokine production
• The required dose and duration of treatment therefore tends to be disease
specific
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
19. GLUCOCORTICOID
BUTTGEREIT F, ET AL. GLUCOCORTICOIDS IN THE TREATMENT OF RHEUMATIC DISEASES. ARTHRITIS & RHEUMATISM 2004.
STAHN C, ET AL. GENOMIC AND NONGENOMIC EFFECTS OF GLUCOCORTICOIDS. NATURE CLINICAL PRACTICE RHEUMATOLOGY 2008.
22. GLUCOCORTICOID
STAHN C, ET AL. GENOMIC AND NONGENOMIC EFFECTS OF GLUCOCORTICOIDS. NATURE CLINICAL PRACTICE RHEUMATOLOGY 2008.
23. DRUGS ACTING ON IMMUNOPHILINS:
CALCINEURIN INHIBITORS >
CYCLOSPORINE
• Brand names: Neoral, Sandimmune, Gengraf
• A lipophilic endecapeptide derived from a fungus (Tolypocladium inflatum)
• Two formulations of cyclosporine are available for oral use
> Oil-based Sandimmune formulation (No longer available)
> Microemulsion Neoral formulation (Better bioavailability and less
variability)
• It is effective in refractory RA, psoriatic arthritis, SLE, autoimmune eye disease
included prophylaxis and treatment of graft rejection following solid organ
transplantation
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
24. CYCLOSPORINE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
25. CYCLOSPORINE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
• The starting dosage of cyclosporine is
2.5 mg/kg/day, usually administered in
divided doses
• To improve efficacy, the dosage can be
increased by 0.5 mg/kg/day at 4- to 8-
week intervals to a maximal dosage of 4
mg/kg/day of the microemulsion
formulation
• In patients whose disease is well
controlled, the dosage of cyclosporine
can be decreased by 0.5 mg/kg/day at
4- to 8-week intervals to determine the
minimal effective dose for the individual
patient
27. DRUGS ACTING ON IMMUNOPHILINS:
CALCINEURIN INHIBITORS >
TACROLIMUS
• Brand names: : Prograf, Envarsus XR, Astagraf XL, Hecoria
• Previously known as FK506
• A macrolide derived from an actinomycete and is widely used in organ
transplantation (Heart, liver, kidney) as an alternative to cyclosporine
• Second-line therapy for the short-term and non-continuous chronic
treatment of moderate to severe atopic dermatitis
• Studies in rheumatic autoimmune disease are less advanced
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
28. TACROLIMUS
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
29. TACROLIMUS
• Adverse effects experienced by patients receiving tacrolimus are similar to
those experienced by patients receiving cyclosporine
• The principal adverse effects of tacrolimus are tremor, headache, nausea,
diarrhea, hypertension, and renal impairment
• Anaphylactic reactions have been reported in animals and humans
following intravenous administration, most likely due to the polyoxyl-60-
hydrogenated castor oil vehicle
CLINICAL GUIDELINES FOR TRANSPLANT MEDICATIONS 2019.
30. DRUGS ACTING ON IMMUNOPHILINS:
TARGET-OF-RAPAMYCIN INHIBITORS >
SIROLIMUS
• Brand name: Rapamune
• Sirolimus (Rapamycin) is a macrolide lactone
• Produced by the actinomycetes (Streptomyces hygroscopicus)
• It is used to prevent rejection reactions
• Although it is a structural analogue of tacrolimus, it acts somewhat differently
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
33. DRUG INTERACTION WITH
CALCINEURIN INHIBITORS AND
TARGET-OF-RAPAMYCIN INHIBITORS
WHAT’S NEW IN KIDNEY TRANSPLANTATION. CONSULT QD 2018.
34. CYTOSTATICS:
ALKYLATING AGENTS >
CYCLOPHOSPHAMIDE
• Brand names: Cytoxan, Neosar, Cytoxan Lyophilized
• Cyclophosphamide was introduced as a cytotoxic agent in 1958
• In combination with glucocorticoids, cyclophosphamide is particular
effective as a remission induction agent in severe SLE and necrotizing
vasculitis
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
35. CYCLOPHOSPHAMIDE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
36. CYCLOPHOSPHAMIDE
• Indications
> Autoimmune diseases
>> Organ-threatening SLE
>> Systemic necrotizing vasculitis
>> Goodpasture’s syndrome
>> Autoimmune disease–associated interstitial lung disease
>> Inflammatory eye disease
> Malignancy
>> Lymphoma
>> Multiple myeloma
>> Leukemias
>> Breast carcinoma
>> Adenocarcinoma of ovary
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
37. CYCLOPHOSPHAMIDE
• Dosages for IV pulse therapy with
cyclophosphamide range from 0.5
to 1 g/m2
• The dosage for oral therapy is 2
mg/kg
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
38. CYCLOPHOSPHAMIDE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
• Side effects
> Nausea and vomiting
> Alopecia
> Myelosuppression
> Mucositis
> Enteritis
> Hemorrhagic cystitis
> Pericardial effusion and tamponade (Rare)
39. CYTOSTATICS:
INHIBITORS OF NUCLEOTIDE SYNTHESIS >
MYCOPHENOLATE MOFETIL
• Brand name: Cellcept
• Mycophenolate mofetil (MMF), a
prodrug, is the inactive 2-
morpholinoester of mycophenolic
acid, which is hydrolyzed to the
active mycophenolic acid (MPA),
an antibiotic with
immunosuppressive effects
• Purine synthesis inhibitors
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
41. MYCOPHENOLATE MOFETIL
• MMF is used as a safer alternative to cytostatic agents in the treatment of several
rheumatic diseases
> SLE
> Systemic sclerosis
> Vasculitis
> Inflammatory muscle disease
• Effective daily dosages of MMF range from 0.5 to 1.5 g twice a day
• Side effects
> MMF is generally well tolerated
> The most common adverse effects are gastrointestinal, such as diarrhea, nausea,
abdominal pain, and vomiting
> Occasional infections, leukopenia, lymphocytopenia, and elevated liver enzymes
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
42. CYTOSTATICS:
INHIBITORS OF NUCLEOTIDE SYNTHESIS >
LEFLUNOMIDE
• Brand name: Arava
• Leflunomide is an immunosuppressive disease-modifying antirheumatic drug
(DMARD)
• Used in active moderate-to-severe rheumatoid arthritis and psoriatic arthritis
• It is a pyrimidine synthesis inhibitor that works by inhibiting dihydroorotate
dehydrogenase
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
43. LEFLUNOMIDE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
45. CYTOSTATICS:
ANTIMETABOLITES >
AZATHIOPRINE
• Brand names: Imuran, Azasan
• Azathioprine is a prodrug that is converted to 6-mercaptopurine (6-MP)
• 6-MP is a purine analogue that acts as a cycle-specific antimetabolite
chemotherapeutic agent and interferes with the synthesis of nucleotides,
thereby inhibiting proliferation of lymphocytes
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
46. AZATHIOPRINE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
47. AZATHIOPRINE
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
• Azathioprine is often started at a
dose of 1 mg/kg daily, and if this
dose is tolerated, it is increased to 2
to 2.5 mg/kg after 2 to 4 weeks
• A gradual increase in dose is often
better tolerated
• The onset of immunosuppressive
effects is relatively slow, over several
weeks
49. AZATHIOPRINE
CLINICAL GUIDELINES FOR TRANSPLANT MEDICATIONS 2019.
• Drug interaction
> Xanthine oxidase inhibitors (Allopurinol and febuxostat)
>> Azathioprine is metabolized by xanthine oxidase
>> Xanthine oxidase inhibitors may inhibit azathioprine metabolism, thus
resulting in increased azathioprine activity and toxicity
> Angiotensin-converting enzyme inhibitors (Captopril, enalapril)
>> ACEIs may induce anemia and severe leukopenia
> Warfarin
>> Azathioprine may inhibit the anticoagulant effect of warfarin
50. CYTOSTATICS:
ANTIMETABOLITES >
METHOTREXATE
• Brand names: Trexall, Rasuvo, Otrexup, Methotrexate LPF Sodium
• Methotrexate (Analog of folic acid) is commonly used in the treatment of a wide
range of malignant and non-malignant diseases
• Indications
> Rheumatoid arthritis
> Juvenile idiopathic arthritis
> Psoriasis
> Inflammatory bowel diseases
> Multiple sclerosis
> Vasculitis
> Systemic lupus erythematosus
> Transplantation
BEDOUI Y, ET AL. METHOTREXATE AN OLD DRUG WITH NEW TRICKS. INT. J. MOL. SCI. 2019.
53. ANTIBODIES:
POLYCLONAL ANTIBODIES
• Polyclonal antibodies inhibit T lymphocytes and cause their lysis, which is both
complement mediated cytolysis and cell-mediated opsonization followed by
removal of reticuloendothelial cells from the circulation in the spleen and liver
• Polyclonal antibodies inhibit cell-mediated immune reactions
> Graft rejection
> Delayed hypersensitivity: tuberculin skin reaction
> Graft-versus-host disease (GVHD)
• Side effects
> Infections: CMV
> Serum sickness
> Post-transplant lymphoproliferative disorders (PTLD)
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
54. ANTIBODIES:
T-CELL RECEPTOR DIRECTED ANTIBODIES >
MUROMONAB
• Brand name: Orthoclone OKT3
• OKT3 (R) is presently the only approved anti-CD3 antibody
• It is a mouse anti-CD3 monoclonal antibody of the IgG2a type
• It prevents T-cell activation and proliferation by binding the T-cell receptor
complex present on all differentiated T cells
• Clinically used to control the steroid and/or polyclonal antibodies resistant
acute rejection episodes
• Side effects
> Excessive immunosuppression
> Neutralizing antibodies against the drug
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
55. ANTIBODIES:
B-CELL RECEPTOR DIRECTED ANTIBODIES >
RITUXIMAB
PIERPONT TM, ET AL. PAST, PRESENT, AND FUTURE OF RITUXIMAB—THE WORLD’S FIRST ONCOLOGY MONOCLONAL ANTIBODY THERAPY. FRONTIERS IN ONCOLOGY 2018.
• Brand names: Rituxan, Truxima,
Ruxience, Mebthera
• Rituximab is a chimeric mouse/human
monoclonal antibody (mAb) therapy
with binding specificity to CD20
• Indications
> Rheumatoid Arthritis
> Granulomatosis with polyangiitis
(Wegener’s granulomatosis)
> Microscopic polyangiitis
> Non–Hodgkin’s lymphoma
> Chronic lymphocytic leukemia
56. RITUXIMAB
PIERPONT TM, ET AL. PAST, PRESENT, AND FUTURE OF RITUXIMAB—THE WORLD’S FIRST ONCOLOGY MONOCLONAL ANTIBODY THERAPY. FRONTIERS IN ONCOLOGY 2018.
57. RITUXIMAB
PIERPONT TM, ET AL. PAST, PRESENT, AND FUTURE OF RITUXIMAB—THE WORLD’S FIRST ONCOLOGY MONOCLONAL ANTIBODY THERAPY. FRONTIERS IN ONCOLOGY 2018.
• Side effects
> Nausea
> Hives
> Headache
> Itching
> A sensation of swelling of the tongue or throat
> Irregular heart rhythms
> Severe decreases in red or white blood cells and platelets
> Infections: hepatitis B or C, shingles
58. ANTIBODIES:
IL-2 RECEPTOR DIRECTED ANTIBODIES >
BASILIXIMAB, DACLIZUMAB
VAN LAAR JM. IMMUNOSUPPRESSIVE DRUGS. KELLEY AND FIRESTEIN'S TEXTBOOK OF RHEUMATOLOGY (10TH ED) 2017.
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
• Brand names: Simulect (Basiliximab),
Zenapax (Daclizumab)
• The IL-2a (CD25, T-cell activation antigen,
TAC) is expressed only by the already
activated T lymphocytes
• Basiliximab and daclizumab are
mouse/human anti-Tac antibodies
• These drugs act by binding the IL-2a
receptor's α chain, preventing the IL-2
induced clonal expansion of activated
lymphocytes and shortening their survival
• They are used in the prophylaxis of the
acute organ rejection after the bilateral
kidney transplantation
Basiliximab
Daclizumab
59. OTHER DRUGS:
INTERFERONS >
IFN-ß
• Brand names: Avonex, Rebif, Avonex Prefilled Syringe, Avonex Pen
• IFN-β suppresses the production of Th1 cytokines and the activation of
monocytes
• It is used to slow down the progression of multiple sclerosis
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
60. OTHER DRUGS:
TNF BINDING PROTEINS >
INFLIXIMAB, ADALIMUMAB,
ETANERCEPT
RATHEE P, ET AL. IMMUNOSUPPRESSANTS: A REVIEW. THE PHARMA INNOVATION – JOURNAL 2012;1(12):90-101.
• Brand names: Remicade (Infliximab), Humira (Adalimumab), Enbrel
(Etanercept)
• A TNF-α binding protein is a monoclonal antibody (Infliximab, adalimumab)
or a circulating receptor (Etanercept) that binds to TNF-α and prevent it from
inducing the synthesis of IL-1 and IL-6 and the adhesion of lymphocyte
activating molecules
• They are used in the treatment of rheumatoid arthritis, ankylosing spondylitis,
Crohn's disease and psoriasis